NASDAQ : EXOZ
eXoZymes, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.13 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 38.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 38.33M |
| Enterprise Value | 33.76M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.28M |
| Shares Outstanding | 9.28M |
| Shares Change (YoY) | +11.18% |
| Shares Change (QoQ) | +2.38% |
| Owned by Insiders (%) | 22.76% |
| Owned by Institutions (%) | 43.65% |
| Float | 7.17M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 10.49 |
| P/TBV Ratio | 10.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.81 |
| Quick Ratio | 3.63 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -187.16% |
| Return on Assets (ROA) | -74.74% |
| Return on Invested Capital (ROIC) | -98.72% |
| Return on Capital Employed (ROCE) | -165.90% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$318,465 |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -105,205 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -67.34% |
| 50-Day Moving Average | 5.68 |
| 200-Day Moving Average | 7.76 |
| Relative Strength Index (RSI) | 36.29 |
| Average Volume (20 Days) | 13,522 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 17,654 |
| Short Previous Month | 18,469 |
| Short % of Shares Out | 0.19% |
| Short % of Float | 0.25% |
| Short Ratio (days to cover) | 1.92 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.56M |
| Pretax Income | -10.30M |
| Net Income | -10.19M |
| EBITDA | -10.26M |
| EBIT | -10.56M |
| Earnings Per Share (EPS) | -$1.20 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.65M |
| Total Debt | 1.09M |
| Net Cash | 4.57M |
| Net Cash Per Share | $0.49 |
| Equity (Book Value) | 3.65M |
| Book Value Per Share | 0.39 |
| Working Capital | 4.55M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.00M |
| Capital Expenditures | -145,901 |
| Depreciation & Amortization | 296,298 |
| Net Borrowing | -53,181 |
| Free Cash Flow | -7.14M |
| FCF Per Share | -$0.77 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.18% |
| Shareholder Yield | -11.18% |
| Earnings Yield | -29.11% |
| FCF Yield | -18.63% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |